Vaccines for lyssaviruses other than rabies

References

• Tordo N, Poch O. Structure of rabies virus. In: Rabies. Campbell JB, Charlton KM (Eds). Kluwer Academic Publishers, MA, USA (1988).
   Google Scholar
• Gaudin Y, Ruigrok RWH, Tuffereau C, Knossow M, Flamand A. Rabies virus glycoprotein is a trimer. Virology 187, 627–632 (1992).
   PubMed Web of Science ®Google Scholar
• Dietzschold B, Wunner WH, Wiktor TJ et al. Characterization of an antigenic determinant of the glycoprotein that correlates with pathogenicity of rabies virus. Proc. Natl Acad. Sci. USA 80, 70–74 (1983).
   PubMed Web of Science ®Google Scholar
• Prehaud C, Coulon P, Lafay F, Thiers C, Flamand A. Antigenicity site II of the rabies virus glycoprotein: structure and role in viral virulence. J. Virol.62, 1–7 (1988).
   PubMed Web of Science ®Google Scholar
• Thoulouze MI, Lafage M, Schachner M, Hartmann U, Cremer H, Lafon M. The neural cell adhesion molecule is a receptor for rabies virus. J. Virol.72, 7181–7190 (1998)
   PubMed Web of Science ®Google Scholar
• Perrin P, Thibodeau L, Sureau P. Rabies immunosomes (subunit vaccine) structure and immunogenicity. Pre and post exposure protection studies. Vaccine 3, 325 (1985).
   PubMedGoogle Scholar
• Dietzschold B, Gore M, Marchandier D et al. Structural and immunological characterization of a linear virus neutralizing epitope of the rabies virus glycoprotein and its possible use in a synthetic vaccine. J. Virol. 64, 3804–3809 (1990).
   PubMedGoogle Scholar
• Coulon P, Lafay F, Flamand A. Rabies virus antigenicity: an overview. Onderstepoort J. Vet. Res. 60, 271–275 (1993).
   Google Scholar
• Coll JM. The glycoprotein G of rhabdoviruses. Arch. Virol.140, 827–851 (1995).
   PubMed Web of Science ®Google Scholar
• Mebatsion T, Weiland F, Conzelmann KK. Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane spike glycoprotein G. J. Virol. 73, 242–250 (1999).
   PubMed Web of Science ®Google Scholar
• Hooper DC, Pierard I, Modelska A et al. Rabies ribonucleocapsid as an oral immunogen and immunological enhancer. Proc. Natl Acad. Sci. USA 91, 10908–10912 (1994).
   PubMed Web of Science ®Google Scholar
• Dietzschold B, Wang H, Rupprecht C et al. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein. Proc. Natl Acad. Sci. USA 84, 9165–9169 (1987).
   PubMed Web of Science ®Google Scholar
• Dietzshold B, Lafon M, Wang H et al. Analysis of protective immune mechanisms induced by rabies nucleoprotein. In: Genetics and Pathogenicity of Negative Strand Viruses. Kolakofsky D, Mahy BWJ (Eds). Elsevier Science Publishers BV, Amsterdam, The Netherlands 295–305 (1989).
   Google Scholar
• Fu ZF, Dietzschold B, Schumacher CL, Wunner WH, Ertl HCJ, Koprowski H. Rabies virus nucleoprotein expressed in and purified from insect cells is efficacious as a vaccine. Proc. Natl Acad. Sci. USA 88, 2001–2005 (1991).
   PubMed Web of Science ®Google Scholar
• Fujii H, Takita-Sonoda Y, Mifune K, Kirai K, Nishizono A, Mannen K. Protective efficacy in mice of post-exposure vaccination with vaccinia virus recombinant expressing either rabies virus glycoprotein or nucleoprotein. J. Gen. Virol.75, 1339–1344 (1994).
   PubMedGoogle Scholar
• Drings A, Jallet C, Chambert B, Tordo N, Perrin P. Is there an advantage to including the nucleoprotein in a rabies glycoprotein subunit vaccine? Vaccine 17, 1549–1557 (1999).
   PubMedGoogle Scholar
• Nel LH, Niezgoda M, Hanlon CA, Morril PA, Yager PA, Rupprecht CE. A comparison of DNA vaccines for the rabies-related virus, Mokola. Vaccine 21 (19–20), 2598–2606 (2003).
   PubMedGoogle Scholar
• Bourhy H, Kissi B, Tordo N. Molecular diversity of the Lyssavirus genus. Virology194, 70–81 (1993).
   PubMed Web of Science ®Google Scholar
• Gould AR, Hyatt AD, Lunt R et al. Characterisation of a novel lyssavirus isolated from Pteropid bats in Australia. Virus Res. 54, 165–187 (1998).
   PubMed Web of Science ®Google Scholar
• Jackson AC. Pathogenesis In: Rabies. Jackson AC, Wunner AH (Eds). Elsevier Science, Academic Press, CA, USA, 245–282 (2002).
   Google Scholar
• Centers for Disease Control. Recovery of a patient from clinical rabies – Wisconsin, USA. Morb. Mortal. Wkly. Rep. 53(50), 1171–1173 (2004).
   Google Scholar
• Kuzmin IV, Orciari LA, Arai YT et al. Bat lyssaviruses (Aravan and Khujand) from Central Asia: phylogenetic relationships according to N, P and G gene sequences. Virus Res. 97, 65–79 (2003).
   PubMed Web of Science ®Google Scholar
• Arai YY, Kuzmin IV, Kameoka Y, Botvinkin AI. New lyssavirus genotype from lesser mouse-eared bats (Myotis blythi), Kyrghyzstan. Emerg. Infect. Dis. 9(3), 333–337 (2003).
   PubMed Web of Science ®Google Scholar
• Botvinkin AD, Poleschuk EM, Kuzmin IV et al. Novel lyssaviruses isolated from bats in Russia. Emerg. Infect. Dis. 9(12), 1623–1625 (2003).
   PubMed Web of Science ®Google Scholar
• Badrane H, Bahloul C, Perrin P, Tordo N. Evidence of two Lyssavirus phylogroups with distinct pathogenicity and immunogenicity. J. Virol. 75, 3268–3276 (2001).
   PubMed Web of Science ®Google Scholar
• Von Teichman B, de Koker WC, Bosch SJE, Meredith CD, Bingham J. Mokola virus infection: description of recent South African cases and a review of virus epidemiology. J. SA Vet. Assoc.69(4), 169–171 (1998).
   PubMedGoogle Scholar
• Nel L, Jacobs J, Jaftha J, von Teichman B, Bingham J. New cases of Mokola virus infection in South Africa: A genotypic comparison of southern african virus isolates. Virus Genes20(2), 103–106 (2000).
   PubMed Web of Science ®Google Scholar
• Tuffereau C, LeBlois H, Bėnėjean J, Coulon P, Lafay F, Flamand A. Arginine or lysine in position 333 of ERA and CVS glycoprotein is necessary for rabies virulence in adult mice. Virology172, 206–212 (1989).
   PubMed Web of Science ®Google Scholar
• Desmezieres E, Maillard AP, Gaudin Y, Tordo N, Perrin P. Differential stability and fusion activity of Lyssavirus glycoprotein trimers. Virus Res. 91, 181–187 (2003).
   PubMedGoogle Scholar
• Rupprecht CE, Hanlon CA, Hemachudha T. Rabies re-examined. Lancet Infect. Dis. 2(6), 327–343 (2002).
   PubMed Web of Science ®Google Scholar
• Smith JS. Rabies virus. In: Manual of Clinical Microbiology.Murray PR (Ed.). American Society for Microbiology, Washington DC, USA, 1099–1106 (1999).
   Google Scholar
• Dreesen DW. A global review of rabies vaccines for human use. Vaccine 15(Suppl.), S2–S6 (1997).
   Google Scholar
• World Health Organization. Field application of oral rabies vaccines for dogs: report of a WHO consultation organized in collaboration with the Office International des Epizooties (OIE). WHO/EMC/ZDI/98.15 (1998).
   Google Scholar
• Schumacher CL, Coulon P, Lafay F et al. SAG-2 oral rabies vaccine. Onderstepoort J. Vet. Res. 60, 459–462 (1993).
   PubMedGoogle Scholar
• Fekadu M, Nesby SL, Shaddock JH, Schumacher CL, Linhart SB, Sanderlin DW. Immunogenicity, efficacy and safety of an oral rabies vaccine (SAG-2) in dogs. Vaccine 14(6), 465–468 (1996).
   PubMed Web of Science ®Google Scholar
• Wandeler AI. Oral immunization against rabies: afterthoughts and foresight. Schweiz Arch. Tierheilkd. 142, 455–462 (2000).
   PubMedGoogle Scholar
• Hammami S, Schumacher C, Cliquet F, Tlatli A, Aubert A, Aubert M. Vaccination of Tunisian dogs with the lyophilised SAG2 oral rabies vaccine incorporated into the DBL2 dog bait. Vet. Res.30, 607–613 (1999).
   PubMedGoogle Scholar
• Palanisamy R, Ramanna BC, Ananda Rao K, Srinivasan VA. Combined vaccination of cattle against FMD and rabies. Microbiologica 15(1), 45–49 (1992).
   PubMedGoogle Scholar
• Aspden K, van Dijk A, Bingham J, Cox D, Passmore J-A, Williamson A-L. Immunogenicity of a recombinant lumpy skin disease virus (neetling vaccine strain) expressing the rabies virus glycoprotein in cattle. Vaccine 20, 2693–2701 (2002).
   PubMedGoogle Scholar
• Benmansour A, Leblois H, Coulon P et al. Antigenicity of rabies virus glycoprotein. J. Virol. 65, 4198–4203 (1991).
   PubMed Web of Science ®Google Scholar
• Schneider LG. Antigenic variants of rabies virus. Comp. Immunol. Microbiol. Infect. Dis. 5(1–3), 101–107 (1982).
   PubMedGoogle Scholar
• Dietzschold B, Rupprecht CE, Tollis M et al. Antigenic diversity of the glycoprotein and nucleocapsid proteins of rabies and rabies-related viruses: implication for epidemiology and control of rabies. Rev. Infect. Dis. 10, S785–S798 (1988).
   Google Scholar
• Fekadu M, Shaddock JH, Sanderlin DW, Smith JS. Efficacy of rabies vaccines against Duvenhage virus isolated from European house bats (Eptesicus serotinus), classic rabies and rabies-related viruses, Vaccine 6, 533–539 (1988).
   PubMed Web of Science ®Google Scholar
• Bourhy H, Kissi B, Lafon M, Sacramento D, Tordo N. Antigenic and molecular characterization of bat rabies virus in Europe. J. Clin. Microbiol.30(9), 2419–2426 (1992).
   PubMed Web of Science ®Google Scholar
• Lafon M, Herzog M, Sureau P. Human rabies vaccines induce neutralising antibodies against the European bat rabies virus (Duvenhage). Lancet2, 515 (1986).
   PubMedGoogle Scholar
• Lafon M, Bourhy H, Sureau P. Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice. Vaccine 6, 362–368 (1988).
   PubMed Web of Science ®Google Scholar
• Herzog M, Fritzell C, Lafage M, Montano Hirose JA, Scott-Algara D, Lafon M. T and B cell human responses to European bat lyssavirus after post-exposure rabies vaccination. Clin. Exp. Immunol. 85, 224–230 (1991).
   PubMedGoogle Scholar
• Fraser GC, Hooper PT, Lunt RA et al. Encephalitis caused by a Lyssavirus in fruit bats in Australia. Emerg. Infect. Dis. 2(4), 327–331 (1996).
   PubMed Web of Science ®Google Scholar
• Hooper PT, Lunt RA, Gould AR et al. A new lyssavirus – the first endemic rabies-related virus recognized in Australia. Bulletin of the Institute Pasteur 95, 209–218 (1997).
   Google Scholar
• Bahloul C, Jacob Y, Tordo N, Perrin P. DNA-based immunization for exploring the enlargement of immunological cross-reactivity against the lyssaviruses. Vaccine 16(4), 417–425 (1998).
   PubMed Web of Science ®Google Scholar
• Hanlon CA, Kuzmin I, Blanton JD, Weldon WC, Manangan JS, Rupprecht CE. Efficacy of rabies biologics against new lyssaviruses from Eurasia. Virus Res. 111(1), 44–54 (2005).
   Google Scholar
• Familusi JB, Moore DL. Isolation of a rabies related virus from the CSF of a child with ‘aseptic meningitis’. Afr. J. Med. Sci.3, 93–96 (1972).
   PubMedGoogle Scholar
• Familusi JB, Osunkoya BO, Moore DL, Kemp GE, Fabiyi A. A fatal human infection with Mokola virus. Am. J. Trop. Med. Hyg. 21, 959–963 (1972).
   PubMed Web of Science ®Google Scholar
• Tordo N, Bourhy H, Sather S, Ollo R. Structure and expression in baculovirus of the Mokola virus glycoprotein: an efficient recombinant vaccine. Virology 194, 59–69 (1993).
   PubMedGoogle Scholar
• Anilionis A, Wunner WH, Curtis PJ. Structure of the glycoprotein gene in rabies virus. Nature 294, 275–278 (1981).
   PubMed Web of Science ®Google Scholar
• Jallet C, Jacob Y, Bahloul C et al. Chimeric lyssavirus glycoproteins with increased immunological potential. J. Virol.73(1), 225–233 (1999).
   PubMed Web of Science ®Google Scholar
• Aspden K, Passmore J, Tiedt F, Williamson A-L. Evaluation of lumpy skin disease virus, a capripoxvirus, as a replication-deficient vaccine vector. J. Gen. Virol. 84, 1985–1996 (2003).
   PubMedGoogle Scholar
• Rupprecht CE, Blass L, Smith K et al. Human infection due to recombinant vaccinia-rabies glycoprotein virus. N. Engl. J. Med.345, 582–586 (2001).
   PubMed Web of Science ®Google Scholar
• Koprowski K, Yusibov V. The green revolution: plants as heterologous expression vectors. Vaccine19, 2735–2741 (2001).
   PubMed Web of Science ®Google Scholar
• Hanlon CA, DeMattos CA, DeMattos CC et al. Experimental utility of rabies virus-neutralizing human monoclonal antibodies in post-exposure prophylaxis. Vaccine 19, 3834–3842 (2001).
   PubMed Web of Science ®Google Scholar
• Badrane H, Tordo N. Host switching in Lyssavirus history from the Chiroptera to the Carnivora orders. J. Virol.75, 8096–8104 (2001).
   PubMed Web of Science ®Google Scholar
• Foley HD, McGettigan JP, Siler CA, Dietzschold B, Schnell MJ. A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection. Proc. Natl Acad. Sci. USA97(26), 14680–14685 (2000).
   PubMedGoogle Scholar
• Yarosh OK, Wandeler AI, Graham FL, Campbell JB, Prevec L. Human adenovirus type 5 vectors expressing rabies glycoprotein. Vaccine 14(13), 1257–1264 (1996).
   PubMed Web of Science ®Google Scholar
• WHO position paper. Rabies vaccines. Wkly Epidemiol. Rec. 77, 109–120 (2002).
   PubMedGoogle Scholar
• Hughes GJ, Smith JS, Hanlon CA, Rupprecht CE. Evaluation of a TaqMan PCR assay to detect rabies virus RNA: influence of sequence variation and application to quantification of viral loads. J. Clin. Microbiol. 42(1), 299–306 (2004).
   PubMed Web of Science ®Google Scholar
• Pastoret P-P, Kappeler A, Aubert M. European rabies control and its history. In: Historical Perspectives of Rabies in Europe and the Mediterranean Basin. King AA, Fooks AR, Aubert M, Wandeler AI (Eds). World Organisation for Animal Health, Paris, France, 337–359 (2004).
   Google Scholar
• King A, Crick J. Rabies-related viruses. In: Rabies. Campbell JB, Charlton KM (Eds), Kluwer academic publishers, BA, USA 177–200 (1988).
   Google Scholar
• Schnell MJ, Tan GS, Dietzschold B. The application of reverse genetics technology in the study of rabies virus (RV) pathogenesis and for the development of novel RV vaccines. J. NeuroVirology 11(1), 76–81 (2005).
   PubMed Web of Science ®Google Scholar
• Fooks AR. The challenge of new and emerging lyssaviruses. Exp. Rev. Vaccines 3(4), 89–92 (2004).
   PubMedGoogle Scholar
• Mebatsion T, Cox JH, Frost JW. Isolation and characterization of 115 street rabies virus isolates from Ethiopia by using monoclonal antibodies: identification of 2 isolates as Mokola and Lagos Bat viruses. JIV166, 972–977 (1992).
   Google Scholar
• Brookes SM, Parsons G, Johnson N, McElhinney LM, Fooks AR. Rabies human diploid cell vaccine elicits cross-neutralising and cross-protecting immune responses against European and Australian bat lyssaviruses. Vaccine23, 4101–4109 (2005).
   PubMed Web of Science ®Google Scholar